Tesa/IPA Protocol (Tesamorelin + Ipamorelin)

Overview

The Tesa/Ipa protocol is a pre-mixed combination product that pairs two growth hormone secretagogues in a single vial: tesamorelin, a synthetic analog of growth-hormone-releasing hormone (GHRH), and ipamorelin, a selective agonist of the ghrelin (GHS-R1a) receptor. The two are combined because they prompt the pituitary to release the body’s own growth hormone through different, potentially complementary pathways.

Tesamorelin is the more clinically established of the pair. It is FDA-approved under the brand name Egrifta, but only for reducing excess abdominal fat in people with HIV-associated lipodystrophy. Ipamorelin has been characterized in preclinical research as a notably selective secretagogue but is not approved for any human use.

The blend itself is not an approved therapeutic product. It is sold for research purposes only, and human data on the specific combination is limited.

How it works

Tesamorelin acts like GHRH, binding pituitary GHRH receptors to stimulate a pulse of growth hormone. In trials it has been reported to preferentially mobilize visceral (abdominal) fat, which is thought to reflect growth hormone’s stronger lipolytic effect on that depot. Ipamorelin works through a separate route — the ghrelin receptor — and was described in its original characterization as the first secretagogue with GH selectivity comparable to GHRH, releasing growth hormone with minimal reported effect on cortisol, prolactin, or ACTH.

By combining a GHRH analog with a ghrelin-receptor agonist, the protocol is intended to engage both signaling arms at once. The clinical effect of the specific combination in humans is not established.

Reported benefits

• Reduction of visceral (abdominal) fat (studied for tesamorelin, primarily in HIV lipodystrophy)
• Stimulation of the body’s own growth hormone release rather than direct GH administration
• A selective GH-release profile attributed to the ipamorelin component in preclinical work
• Interest in body-composition and recovery contexts (largely anecdotal for the blend)

These are reported or studied effects for the individual components, not guaranteed outcomes for the combination.

Considerations & side effects

Because this is a research-market blend rather than an approved product, human safety data on the specific combination is limited. In tesamorelin trials, commonly reported effects included injection-site reactions, joint pain or swelling, fluid retention, and changes in glucose tolerance; growth hormone secretagogues as a class can raise blood sugar and are generally cautioned against in people with active malignancy. Ipamorelin’s human safety profile is far less characterized.

Product purity and the actual ratio of the two peptides can vary widely in the research-chemical market. This information is educational and is not a substitute for evaluation and treatment by a qualified clinician.